Sold as Moviprep, Plenvu. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 16, 2026, FDA lists 4 applications for Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate (sold as Moviprep, Plenvu), first approved Aug 2, 2006, with 0 new uses approved and 0 published complete response letters.
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution | To Be Discontinued | Aug 13, 2026 | Aug 13, 2026 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before ColonoscopyColon Disease · Aalborg University Hospital | Phase 4 | Recruiting | Jun 28, 2022 |
| Aug 2, 2006 | MoviprepNDA 21881 · New dosage form | Salix Pharms | 11 | Marketed |
| Jan 25, 2012 | Peg-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate And Ascorbic AcidANDA 90145 | Novel Labs Inc | 2 | Marketed |
| May 4, 2018 | PlenvuNDA 209381 · New active ingredient | Norgine | 4 | Discontinued |
| Jun 28, 2024 | Peg-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate And Ascorbic AcidANDA 207498 | Taro | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA